Additionally, other research has found that somatic mutations and gene variations in KEAP1 frequently occur in lung cancers and cancer-derived cell lines [36], suggesting that mutation KEAP1 might disrupt its ability to bind NRF2. This evidence concerns the gene NFE2L2 and lung carcinoma.